Aviolat, Hubert http://orcid.org/0000-0001-6235-4996
Pinto, Ricardo Mouro http://orcid.org/0000-0001-6744-2805
Godschall, Elizabeth
Murtha, Ryan
Richey, Hannah E.
Sapp, Ellen
Vodicka, Petr http://orcid.org/0000-0002-6605-9158
Wheeler, Vanessa C.
Kegel-Gleason, Kimberly B.
DiFiglia, Marian
Funding for this research was provided by:
CHDI Foundation
Article History
Received: 4 September 2019
Accepted: 18 November 2019
First Online: 16 December 2019
Competing interests
: KBK-G spouse owns less than 0.1% stock in the following companies: Bristol-Myers Squibb Company, Cisco Systems, Inc., GE Healthcare Life Sciences, Generex Biotechnology Corporation, GlaxoSmithKline, Metabolix Bioplastics, Nanogen, Inc., Nanometrics, Inc., StemCells, Inc. VCW is a paid Scientific Advisory Board member of LoQus23 Therapeutics. VCW has a financial interest in Triplet Therapeutics, a biotherapeutics company developing new therapeutic approaches to address triplet repeat disorders such as Huntington’s disease and Myotonic Dystrophy. Dr. Wheeler’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. Other authors have declared that no conflict of interest exists.